Kodiak Sciences Inc

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Kodiak Sciences reports strong clinical progress and eyes market expansion

Kodiak Sciences Inc showcased strong clinical progress with positive Phase III results and plans to advance all 3 programs into Phase III studies in 2024.
The company's focus on durability, diverse pipeline, and strategic approach position them well in addressing retinal vascular diseases.
While facing challenges in differentiation and long-term efficacy demonstration, Kodiak has opportunities to expand market reach through innovative study designs and patient subgroup exploration.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences (KOD) progresses well with the development of its lead candidate, KSI-301, for treating various retinal vascular diseases. Stiff competition in the target market remains a woe.

Kodiak Sciences (KOD) Focuses on Developing Eye Candidate KSI-301

PALO ALTO, Calif., Dec. 16, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its BEACON Phase 3 clinical trial of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with macular edema due to retinal vein occlusion ("RVO").

Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

Kodiak Sciences (KOD) reports wider-than-expected loss for the third quarter of 2021. Pipeline development remains in focus for the company.

Kodiak Sciences (KOD) Q3 Loss Widens, Eye Candidate in Focus

PALO ALTO, Calif., Nov. 9, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the third quarter ended September 30, 2021.

Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights

PALO ALTO, Calif., Nov. 8, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences: Jefferies London Healthcare Conference (pre-recorded fireside chat available on Thursday, November 18 at 12:00 a.m.

Kodiak Sciences to Present at Upcoming Conferences

ON Semiconductor

Sensient Technologies

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

3 Stocks Insiders Are Buying

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?

Kodiak Sciences Inc. (KOD) Up 15.7% Since Last Earnings Report: Can It Continue?

PALO ALTO, Calif. , Sept. 1, 2021  /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced new seven-year performance stock option awards under a Long-Term Performance Incentive Plan (LTPIP) for named executive officers (NEOs) as well as other eligible Kodiak employees, subject to stockholder approval of the LTPIP at a special meeting expected to be held in October.

Kodiak Sciences Announces New Long-Term Performance Incentive Plan

PALO ALTO, Calif., Aug. 31, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, at 8:45 a.m.

Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Kodiak Sciences (KOD) reports wider-than-expected loss for the second quarter of 2021. Pipeline development remains in focus for the company.

Kodiak Sciences (KOD) Q2 Earnings Lag, Eye Candidate in Focus

PALO ALTO, Calif., Aug. 9, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2021.

Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights

ARK Genomic Revolution Multi-Sector ETF

Regeneron Pharmaceuticals

This mid-cap growth stock could be a long-term winner.

Is This Mid-Cap Biotech Stock a Buy Now?

In December 2019, Kodiak Sciences Inc (NASDAQ: KOD) entered into a funding agreement with Baker Bros Advisors LP, wherein Baker Bros agreed to fund up to $225 million in exchange for the right to 4.5% royalties on Kodiak's potential future net sales of KSI-301 and certain other products.  The royalty was capped at 4.5 times the total amount funded under the Funding Agreement.

Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance Sheet

Why Is Kodiak Sciences Inc. (KOD) Down 4% Since Last Earnings Report?

NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Kodiak Sciences Inc. - KOD

Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.

Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus

The company provided a first-quarter update with news that it's launching another late-stage clinical study of its lead candidate.

Why Kodiak Sciences Stock Is Tumbling Today

PALO ALTO, Calif., May 10, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2021.

Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Kodiak Sciences Inc. (KOD) a New Buy Stock

Kodiak Sciences is expected to have three trial readouts in 2022 with use of its drug KSI-301. If all studies end up being successful, then 3 BLA filings would happen.

Kodiak Sciences Offers Multiple Shots On Goal For Eye Treatments, Multiple Catalysts Expected In 2022

Nordstrom

Nielsen Hlds

PayPal

Cardtronics

Cheniere Energy Partners

Intercept Pharma

MongoDB

StoneCo

With the trading day nearing halfway over, the broad markets were somewhat mixed to close out the week.

Nielsen, Nordstrom, PayPal and More Friday Afternoon Analyst Calls

Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.

Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus

PALO ALTO, Calif., March 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial...

Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Kodiak Sciences Inc (NASDAQ: KOD) announced new data from one-year durability, efficacy, and safety data from the ongoing Phase 1b study evaluating KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degeneration (wet AMD) diabetic macular edema (DME) and retinal vein occlusion (RVO).  Kodiak presented the data at the Angiogenesis, Exudation, and Degeneration 2021 Annual Meeting.

Kodiak Sciences' KSI-301 Shows Durable Benefit In Retinal Disease Settings

PALO ALTO, Calif., Feb. 13, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced promising 1-year durability,...

Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degene

News for Kodiak Sciences Inc Stock (KOD)